高级搜索
邓康俐, 崔殿生, 贾全安, 刘三河, 黄雷, 魏少忠. 新辅助化疗与辅助化疗治疗肌层浸润性膀胱癌的疗效比较[J]. 肿瘤防治研究, 2019, 46(4): 363-366. DOI: 10.3971/j.issn.1000-8578.2019.18.1002
引用本文: 邓康俐, 崔殿生, 贾全安, 刘三河, 黄雷, 魏少忠. 新辅助化疗与辅助化疗治疗肌层浸润性膀胱癌的疗效比较[J]. 肿瘤防治研究, 2019, 46(4): 363-366. DOI: 10.3971/j.issn.1000-8578.2019.18.1002
DENG Kangli, CUI Diansheng, JIA Quan'an, LIU Sanhe, HUANG Lei, WEI Shaozhong. Clinical Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy on Muscle-invasive Bladder Cancer[J]. Cancer Research on Prevention and Treatment, 2019, 46(4): 363-366. DOI: 10.3971/j.issn.1000-8578.2019.18.1002
Citation: DENG Kangli, CUI Diansheng, JIA Quan'an, LIU Sanhe, HUANG Lei, WEI Shaozhong. Clinical Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy on Muscle-invasive Bladder Cancer[J]. Cancer Research on Prevention and Treatment, 2019, 46(4): 363-366. DOI: 10.3971/j.issn.1000-8578.2019.18.1002

新辅助化疗与辅助化疗治疗肌层浸润性膀胱癌的疗效比较

Clinical Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy on Muscle-invasive Bladder Cancer

  • 摘要:
    目的 对接受新辅助和辅助化疗的膀胱癌患者临床疗效进行对比,为化疗时机的选择作初步探索。
    方法 回顾性研究湖北省肿瘤医院2009—2016年诊断为肌层浸润性膀胱癌并在全膀胱术前(新辅助)或术后(辅助)接受了GC方案化疗的患者。主要研究终点是无复发生存期(recurrence-free survival, RFS)。次要研究终点是临床完全缓解率(complete response, CR)。
    结果 共38例肌层浸润性膀胱癌患者纳入研究(22例新辅助+16例辅助)。在中位随访时间点时,新辅助和辅助化疗组的RFS相比较差异无统计学意义(69.6% vs.75.4%, P=0.223)。在中位随访时间点上接受新辅助化疗后病理完全缓解组(pT0)与非完全缓解组(non-pT0)的RFS分别为100%和50%(P=0.012),差异有统计学意义。两组患者在接受化疗治疗后出现3~4级严重血液学不良反应的人数比例相比较差异无统计学意义(P=0.36)。
    结论 接受新辅助或辅助化疗的肌层浸润性膀胱癌患者的RFS相比较差异无统计学意义,新辅助化疗后达到病理完全缓解的患者均未出现肿瘤复发,但尚需更多的研究来证实。

     

    Abstract:
    Objective To compare the clinical outcomes of neoadjuvant versus adjuvant chemotherapy on muscle-invasive bladder cancer patients.
    Methods We retrospectively reviewed the muscle-invasive bladder cancer patients who were treated with radical cystectomy plus neoadjuvant or adjuvant chemotherapy from 2009 to 2016 in Hubei Cancer Hospital. The primary endpoint was recurrence-free survival (RFS). The secondary endpoint was clinical complete response (CR).
    Results A total of 38 muscle-invasive bladder cancer patients were included: 22 patients received neoadjuvant chemotherapy and 16 patients received adjuvant chemotherapy. The RFS at median follow-up time was not significantly different between neoadjuvant and adjuvant groups (69.6% vs. 75.4%, P=0.223). The RFS at median follow-up time between maid patients with pT0 and non-pT0 were significantly different (100% vs. 50%, P=0.012). The incidence rates of grade 3 or 4 thrombocytopenia, anemia and neutropenia were not significantly different between the two groups (P=0.36).
    Conclusion There is no significant difference in RFS between neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer patients treated with radical cystectomy. No recurrence occurs in the patients who achieve pT0 in neoadjuvant chemotherapy group. Further investigations are needed to confirm our results.

     

/

返回文章
返回